AgomAb Therapeutics NV (AGMB)

Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. C9

What they're doing

Between 2026-08-02 and 2026-10-31, public records show 1 signal for AgomAb Therapeutics NV. Most notable: 2026-10-05: Knotnerus Tim Jasper (director) bought $51k of stock. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.

Generated 2026-10-31 from public records.

Signals, last 12 months

  1. Insider purchase
    Knotnerus Tim Jasper (director) bought $51k of stock

Insider transactions

DateInsiderRoleCodeSharesPriceValue
2026-10-21Epstein David RdirectorP5,0008.9$44,500
2026-10-21Epstein David RdirectorP5,0008.86$44,300
2026-10-08Epstein David RdirectorP5,0008.9$44,500
2026-10-06Knotnerus Tim JasperdirectorP5,0008.7$43,500
2026-10-06Kemula Pierre Thadee VictorofficerP2,0008.54$17,080
2026-10-06Kemula Pierre Thadee VictorofficerP5,0008.57$42,850
2026-10-06Kemula Pierre Thadee VictorofficerP3,0008.67$26,010
2026-10-06Epstein David RdirectorP5,0008.7$43,500
2026-10-05Knotnerus Tim JasperdirectorP6,0008.48$50,880
2026-10-05Epstein David RdirectorP5,0008.57$42,850

Federal contracts

No federal contract actions on record for this recipient mapping.

Lobbying

No federal lobbying filings on record for this client mapping.

Public attention

No Wikipedia pageview data linked to this company.

Recent filings